| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 3011- | RosA, | Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition |
| - | in-vitro, | GBM, | SH-SY5Y | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | MCF10 |
| 3008- | RosA, | Rosmarinic acid decreases viability, inhibits migration and modulates expression of apoptosis-related CASP8/CASP3/NLRP3 genes in human metastatic melanoma cells |
| - | in-vitro, | Melanoma, | SK-MEL-28 |
| 3033- | RosA, | Rosemary (Rosmarinus officinalis) Extract Modulates CHOP/GADD153 to Promote Androgen Receptor Degradation and Decreases Xenograft Tumor Growth |
| - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | LNCaP | - | vitro+vivo, | NA, | NA |
| 4899- | Sal, | Anticancer activity of salinomycin quaternary phosphonium salts |
| - | in-vitro, | Var, | NA |
| 4903- | Sal, | Salinomycin: A new paradigm in cancer therapy |
| - | Review, | Var, | NA |
| 5004- | Sal, | Targeting Telomerase Enhances Cytotoxicity of Salinomycin in Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 5003- | Sal, | Salinomycin, as an autophagy modulator-- a new avenue to anticancer: a review |
| - | Review, | Var, | NA |
| 4996- | Sal, | The Molecular Basis for Inhibition of Stemlike Cancer Cells by Salinomycin |
| - | in-vitro, | Var, | NA |
| 4905- | Sal, | Salinomycin as a drug for targeting human cancer stem cells |
| - | Review, | Var, | NA |
| 4910- | Sal, | A medicinal chemistry perspective on salinomycin as a potent anticancer and anti-CSCs agent |
| - | Review, | Var, | NA |
| 5122- | Sal, | Identification of selective inhibitors of cancer stem cells by high-throughput screening |
| - | in-vivo, | BC, | SUM159 | - | NA, | NA, | 4T1 |
| 5121- | Sal, | Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells |
| - | in-vitro, | BC, | NA |
| 6442- | SAO, | Medicinal properties of alpha-santalol, a naturally occurring constituent of sandalwood oil: review |
| - | Review, | RCC, | NA |
| 6444- | SAO, | Sandalwood oil by-product prevents prostate cancer development in mice |
| - | in-vivo, | Pca, | PC12 |
| 6445- | SAO, | Antineoplastic Effects of α-Santalol on Estrogen Receptor-Positive and Estrogen Receptor-Negative Breast Cancer Cells through Cell Cycle Arrest at G2/M Phase and Induction of Apoptosis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MCF-10AT |
| 6451- | SAO, | α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 5041- | SAS, | Cisplatin, | Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism |
| - | in-vitro, | CRC, | NA |
| 5038- | SAS, | Rad, | Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma |
| - | in-vivo, | Melanoma, | B16-F10 |
| 2549- | SDT, | Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation |
| - | Review, | Var, | NA |
| 4488- | Se, | Chit, | PEG, | Anticancer effect of selenium/chitosan/polyethylene glycol/allyl isothiocyanate nanocomposites against diethylnitrosamine-induced liver cancer in rats |
| - | in-vivo, | Liver, | HepG2 | - | in-vivo, | Nor, | HL7702 |
| 4615- | Se, | Rad, | Selenium as an adjuvant for modification of radiation response |
| - | Review, | Nor, | NA |
| 4484- | Se, | Chit, | PEG, | Anti-cancer potential of selenium-chitosan-polyethylene glycol-carvacrol nanocomposites in multiple myeloma U266 cells |
| - | in-vitro, | Melanoma, | U266 |
| 4715- | Se, | The Interaction of Selenium with Chemotherapy and Radiation on Normal and Malignant Human Mononuclear Blood Cells |
| - | in-vitro, | Var, | NA |
| 4734- | SeNPs, | CPT-11, | Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles |
| - | in-vitro, | CRC, | HCT8 | - | in-vivo, | NA, | NA |
| 4603- | SeNPs, | Therapeutic applications of selenium nanoparticles |
| - | Review, | Var, | NA |
| 4480- | SeNPs, | Chit, | Biogenic synthesized selenium nanoparticles combined chitosan nanoparticles controlled lung cancer growth via ROS generation and mitochondrial damage pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HK-2 |
| 4608- | SeNPs, | Selenium Nanoparticles for Biomedical Applications: From Development and Characterization to Therapeutics |
| - | Review, | Var, | NA | - | NA, | AD, | NA |
| 4501- | SeNPs, | Mechanisms of the Cytotoxic Effect of Selenium Nanoparticles in Different Human Cancer Cell Lines |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | L929 |
| 4448- | SeNPs, | Selenium Nanoparticles: A Comprehensive Examination of Synthesis Techniques and Their Diverse Applications in Medical Research and Toxicology Studies |
| - | Review, | Nor, | NA |
| 4473- | SeNPs, | Anti-cancerous effect and biological evaluation of green synthesized Selenium nanoparticles on MCF-7 breast cancer and HUVEC cell lines |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | HUVECs |
| 4472- | SeNPs, | Therapeutic potential of selenium nanoparticles |
| - | Review, | Var, | NA |
| 4471- | SeNPs, | Green synthesis of selenium nanoparticles with extract of hawthorn fruit induced HepG2 cells apoptosis |
| - | in-vitro, | Liver, | HepG2 |
| 4469- | SeNPs, | Selenium Nanoparticles in Cancer Therapy: Unveiling Cytotoxic Mechanisms and Therapeutic Potential |
| - | Review, | Var, | NA |
| 4449- | SeNPs, | PEG-nanolized ultrasmall selenium nanoparticles overcome drug resistance in hepatocellular carcinoma HepG2 cells through induction of mitochondria dysfunction |
| - | in-vitro, | Liver, | HepG2 |
| 4453- | SeNPs, | Selenium Nanoparticles: Green Synthesis and Biomedical Application |
| - | Review, | Var, | NA |
| 4457- | SeNPs, | Selenium nanoparticles: a review on synthesis and biomedical applications |
| - | Review, | Var, | NA | - | NA, | Diabetic, | NA |
| 9281- | SES, SSM, | LIGs, | A comprehensive review on the anti-cancer properties of sesame lignans: chemical composition, molecular mechanisms and prospects |
| - | Review, | Var, | NA |
| 3192- | SFN, | Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention |
| - | in-vitro, | Pca, | PC3 |
| 3182- | SFN, | Sulforaphane Modulates AQP8-Linked Redox Signalling in Leukemia Cells |
| - | in-vitro, | AML, | NA |
| 2166- | SFN, | Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction |
| - | in-vitro, | Oral, | NA | - | in-vivo, | NA, | NA |
| 1498- | SFN, | Prolonged sulforaphane treatment activates survival signaling in nontumorigenic NCM460 colon cells but apoptotic signaling in tumorigenic HCT116 colon cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | NCM460 |
| 1502- | SFN, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 1497- | SFN, | Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells |
| - | in-vitro, | Nor, | PrEC | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 1494- | SFN, | doxoR, | Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model |
| - | in-vivo, | BC, | NA | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 1736- | SFN, | Antitumor and antimetastatic effects of dietary sulforaphane in a triple-negative breast cancer models |
| - | in-vitro, | BC, | NA | - | in-vivo, | BC, | NA |
| 1734- | SFN, | Sulforaphane Inhibits Nonmuscle Invasive Bladder Cancer Cells Proliferation through Suppression of HIF-1α-Mediated Glycolysis in Hypoxia |
| - | in-vitro, | Bladder, | RT112 |
| 3299- | SIL, | Silymarin Effect on Mitophagy Pathway in the Human Colon Cancer HT-29 Cells |
| - | in-vitro, | Colon, | HT29 |
| 3282- | SIL, | Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions |
| - | Review, | Var, | NA |
| 977- | SK, | A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | HMEC |
| 2230- | SK, | Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid